Dollar rebounds despite Fed independence worries; euro slips
Daniel N. Swisher Jr., a director at Corcept Therapeutics Inc. (NASDAQ:CORT), executed a series of stock transactions on April 10, 2025, according to a recent SEC filing. Swisher exercised stock options to acquire 2,200 shares of Corcept’s common stock at a price of $12.13 per share. Subsequently, he sold the same number of shares at a price of $70.22 per share, resulting in a total transaction value of $154,484. The transaction comes as Corcept shows remarkable performance, with InvestingPro data showing a 187% return over the past year and strong financial health metrics.
The sale was conducted as part of a pre-established 10b5-1 trading plan, which Swisher adopted on August 1, 2024. Following these transactions, Swisher no longer holds any shares directly from this particular exercise and sale. According to InvestingPro analysis, Corcept currently appears fairly valued, with a market capitalization of $7.1 billion and impressive gross profit margins of 98%. For deeper insights into Corcept’s valuation and 16 additional ProTips, subscribers can access the comprehensive Pro Research Report.
In other recent news, Corcept Therapeutics has initiated a Phase 2 trial named BELLA to evaluate the efficacy and safety of relacorilant in combination with nab-paclitaxel and bevacizumab for patients with platinum-resistant ovarian cancer. This follows the successful results from the pivotal Phase 3 ROSELLA trial, which demonstrated that the combination therapy led to a 30% reduction in disease progression risk and improved overall survival rates. The company plans to submit a New Drug Application in the third quarter of 2025, with submissions in the European Union to follow shortly thereafter.
Analysts have responded positively to these developments. Piper Sandler increased Corcept’s stock price target to $131, maintaining an Overweight rating, and highlighted the potential $1 billion sales opportunity for relacorilant in the PROC market. Truist Securities also raised its target to $150, citing the drug’s competitive performance compared to similar treatments and its potential peak sales of approximately $800 million by 2035. H.C. Wainwright followed suit, raising its target to $150 and maintaining a Buy rating, noting the favorable comparison of relacorilant’s performance against AbbVie (NYSE:ABBV)’s Elahere.
The ROSELLA trial’s success is notable for its dual primary endpoints of progression-free survival and overall survival, reflecting significant advancement in treatment for platinum-resistant ovarian cancer. The trial involved 381 patients across multiple international sites, underscoring its comprehensive nature. Corcept’s Chief Development Officer expressed optimism about establishing relacorilant as a new standard of care for this challenging form of ovarian cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.